4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Sunho Biologics, Inc. (2898) operates in the Biotechnology industry and is headquartered in Huzhou, China with about 128 employees. Its market capitalization is roughly CNY 1 billion. In the fiscal year ended 2024-12-31, 2898 reported CNY 0M in revenue and (CNY 80M) in net income.
Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems.
Interactive charts & full statements →
| Income statement | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Revenue | CNY 0M | CNY 0M | CNY 2M |
| Gross Profit | CNY 0M | CNY 0M | CNY 0M |
| Operating Income (EBIT) | (CNY 101M) | (CNY 66M) | (CNY 46M) |
| Net Income | (CNY 80M) | (CNY 133M) | (CNY 52M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Assets | CNY 561M | CNY 290M | CNY 71M |
| Total Liabilities | CNY 49M | CNY 395M | CNY 72M |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2898 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms